RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rapt · stock forecast · 15 analysts (3M) · FMP · updated Mar 26, 2026
Analyst Rating & Consensus
Based on 15 Wall Street analysts in the past 3 months
Hold
15 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$58.00
Consensus
$58.00
-0.0% upside
Low
$58.00
Median: $58 · Last Close: $58.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $57.90 | ↓ 0.20% |
1-day model range: $57.89–$57.91. Peak: $57.91 (-0.20%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RAPT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-21 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2026-01-21 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2026-01-20 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2026-01-20 | Clear Street | Downgrade ↓ | Buy→Hold |
| 2026-01-20 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-01-20 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2026-01-20 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-11-12 | JP Morgan | Maintains | Overweight→Overweight |
| 2025-11-07 | Barclays | Maintains | Overweight→Overweight |
| 2025-11-03 | Wells Fargo | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on RAPT Therapeutics, Inc. (RAPT) stock. Of the recent 65 rating actions, 4 were upgrades and 16 were downgrades. 15 analysts currently cover RAPT.
Analyst Recommendation Trends
RAPT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 4.6% YoY
Revenue Next Year
$10M
↑ 1226.1% YoY
EPS This Year
$-2.40
EPS Next Year
$-3.17
↑ 32.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast RAPT EPS of $-2.40 for the current fiscal year, based on estimates from 4 analysts. The RAPT revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RAPT stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RAPT price target is $58.00 (-0.0% upside), with an analyst consensus of Hold.
The RAPT short-term stock prediction for tomorrow is $57.90 (-0.20%).
RAPT Therapeutics, Inc. trades on NASDAQ under the ticker RAPT. The RAPT stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 27% of covering analysts.
Frequently asked questions
RAPT forecast · 8 questionsAccording to 15 Wall Street analysts, the average 12-month RAPT price target is $58.00, with a high forecast of $58.00 and a low of $58.00. The median price target is shown in the chart above when available. This implies -0.0% potential upside from the current price of $58.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.